Integra LifeSciences (NASDAQ:IART) Upgraded by Argus to Buy Rating

Integra LifeSciences (NASDAQ:IART) was upgraded by analysts at Argus from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday, MarketBeat reports. The firm presently has a $25.00 target price on the life sciences company’s stock. Argus’ price target indicates a potential upside of 45.35% from the stock’s current price.

Other research analysts also recently issued reports about the stock. Citigroup raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and lifted their price target for the stock from $11.00 to $16.00 in a research note on Thursday, May 28th. Truist Financial cut their price objective on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating for the company in a research note on Wednesday, April 15th. Wells Fargo & Company lifted their target price on shares of Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. Wall Street Zen raised shares of Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 13th. Finally, Weiss Ratings raised Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. One equities research analyst has rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average price target of $16.20.

Integra LifeSciences Stock Performance

Integra LifeSciences stock opened at $17.20 on Thursday. Integra LifeSciences has a fifty-two week low of $8.70 and a fifty-two week high of $18.19. The company has a debt-to-equity ratio of 1.75, a quick ratio of 1.95 and a current ratio of 3.38. The stock has a market cap of $1.34 billion, a P/E ratio of -2.66, a price-to-earnings-growth ratio of 1.23 and a beta of 1.24. The firm’s fifty day moving average price is $13.76 and its 200-day moving average price is $12.29.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Tuesday, May 5th. The life sciences company reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.13. The business had revenue of $391.92 million for the quarter, compared to analysts’ expectations of $381.81 million. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The firm’s revenue was up 2.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.41 earnings per share. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. On average, equities research analysts expect that Integra LifeSciences will post 2.44 earnings per share for the current fiscal year.

Institutional Trading of Integra LifeSciences

Large investors have recently added to or reduced their stakes in the stock. Osaic Holdings Inc. grew its holdings in shares of Integra LifeSciences by 36.6% during the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after acquiring an additional 1,104 shares during the period. State of Tennessee Department of Treasury boosted its position in shares of Integra LifeSciences by 7.9% during the fourth quarter. State of Tennessee Department of Treasury now owns 26,745 shares of the life sciences company’s stock valued at $332,000 after purchasing an additional 1,964 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Integra LifeSciences by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock valued at $889,000 after purchasing an additional 1,975 shares in the last quarter. Capital Fund Management S.A. grew its stake in Integra LifeSciences by 5.7% in the third quarter. Capital Fund Management S.A. now owns 37,322 shares of the life sciences company’s stock worth $535,000 after purchasing an additional 1,997 shares during the period. Finally, Global Retirement Partners LLC bought a new position in Integra LifeSciences in the fourth quarter worth $25,000. Institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.